ADB Approves $400 Million Loan to Boost Ease of Doing Business in the Philippines 
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform 
Coca-Cola’s Costa Coffee Sale Faces Uncertainty as Talks With TDR Capital Hit Snag 
Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise 
SpaceX Insider Share Sale Values Company Near $800 Billion Amid IPO Speculation 
SoftBank Shares Slide as Oracle’s AI Spending Plans Fuel Market Jitters 
China Adds Domestic AI Chips to Government Procurement List as U.S. Considers Easing Nvidia Export Curbs 
EU Court Cuts Intel Antitrust Fine to €237 Million Amid Long-Running AMD Dispute 
Trump’s Approval of AI Chip Sales to China Triggers Bipartisan National Security Concerns 
Air Transat Reaches Tentative Agreement With Pilots, Avoids Strike and Restores Normal Operations 
JD.com Pledges 22 Billion Yuan Housing Support for Couriers as China’s Instant Retail Competition Heats Up 
Air Force One Delivery Delayed to 2028 as Boeing Faces Rising Costs 
Rio Tinto Signs Interim Agreement With Yinhawangka Aboriginal Group Over Pilbara Mining Operations 
Intel’s Testing of China-Linked Chipmaking Tools Raises U.S. National Security Concerns 
Microsoft Unveils Massive Global AI Investments, Prioritizing India’s Rapidly Growing Digital Market 
EssilorLuxottica Bets on AI-Powered Smart Glasses as Competition Intensifies 
Samsung SDI Secures Major LFP Battery Supply Deal in the U.S. 
UK’s AstraZeneca will buy US drugmaker Alexion Pharmaceuticals for $39 billion to diversify from its cancer business to rare-disease and immunology drugs.
AstraZeneca would give Alexion shareholders $60 in cash and about $115 worth of equity per share, either in AstraZeneca’s dollar-denominated American Depositary Shares or in UK-traded ordinary shares.
Alexion shares closed at around $121 apiece on Friday.
According to AstraZeneca CEO Pascal Soriot, the acquisition of Alexion would open up a tremendous opportunity for AstraZeneca to accelerate its development in immunology, while getting into a new segment of disease, physicians, and patients they haven's covered so far.
Soliris, Alexion’s best-selling drug, is used against a range of rare immune-disorders. Among those is paroxysmal nocturnal hemoglobinuria (PNH), which causes anemia and blood clots.
Soliris' revenue rose 3.6 percent in the first nine months to $3 billion.
An improved version of Soliris called Ultomiris has bigger market potential, expecting more growth by introducing rare-disease treatments to China and other emerging markets.
Both companies have approved the deal, which is expected to close in the third quarter of 2021.
AstraZeneca has a planned capital increase of about $25 billion after the deal closure, driven by the stellar growth of new cancer drugs.
Last week, AstraZeneca was conducting further research to confirm whether its COVID-19 vaccine could be 90 percent effective, potentially slowing its rollout. Meanwhile, a rival vaccine from Pfizer was launched in the UK and approved for use in the US.
AstraZeneca was once seen as leading the race to develop a COVID-19 vaccine but has fallen behind Pfizer and its partner BioNTech, as well as Moderna, whose vaccines have shown greater efficacy in late-stage clinical trials.
